Glucagon-Like Peptide-1 Receptor Agonist Therapy Does Not Increase Gastrointestinal Adverse Events in Patients with Inflammatory Bowel Disease.

GLP-1 受體促效劑治療不會增加發炎性腸道疾病患者的腸胃道不良事件。